医药赛道火热，近2个月超20只新品扎堆上报！有医药主题基金却濒临清盘？

Core Viewpoint - The innovative drug sector is experiencing significant growth, with multiple thematic funds rising over 50% in value, prompting fund companies to accelerate their investments in the pharmaceutical sector [1][2][7]. Fund Activity - Over 20 pharmaceutical-themed funds have been reported in just two months, significantly increasing compared to the first quarter of the year [2][3]. - More than 100 funds have seen gains exceeding 50% this year, with some nearing 100% growth, primarily linked to the innovative drug sector [2]. Fund Performance and Risks - Despite the overall positive trend, some thematic funds are facing liquidation risks, such as the 富荣医药健康混合 fund, which may trigger contract termination if its scale falls below 200 million yuan by June 2025 [9][10]. - The 富荣医药健康混合 fund has reported a total scale of less than 13 million yuan as of the latest quarter, leading to a suspension of subscription activities [11]. Manager Insights - Fund managers remain optimistic about the innovative drug sector, citing potential catalysts and ongoing overseas licensing discussions [7][8]. - The investment logic surrounding innovative drugs is gaining consensus, driven by accelerated performance growth and significant business development transactions [8].